April 4, 2007
Genzyme, Bayer seek leukemia drug approval
By Matthew L. Brown
Following positive clinical trial data, Cambridge-based Genzyme Corp., which has operations in Framingham, has submitted a license application with the U.S. Food and Drug Administration for a leukemia treatment.
Genzyme is working with Bayer HealthCare on the treatment, which is called Campath.
Campath is currently approved for patients who have already received a certain treatment, but have failed therapy.
Now, the company would like the drug to be approved for "first-line treatment" of B-cell lymphocytic leukemia, the most prevalent form of adult leukemia, which affects about 120,000 people in the U.S. and Europe.
Genzyme is working with Bayer HealthCare on the treatment, which is called Campath.
Campath is currently approved for patients who have already received a certain treatment, but have failed therapy.
Now, the company would like the drug to be approved for "first-line treatment" of B-cell lymphocytic leukemia, the most prevalent form of adult leukemia, which affects about 120,000 people in the U.S. and Europe.
WBJ Web Partners
Most Recent
Most Recent
0 Comments